Table 5

Unadjusted and adjusted logistic regression models examining the factors associated with seropositivity

Seropositivity rate, n (%)Unadjusted OR (95% CI)Adjusted OR (95% CI)P value
Age >65 years, n=246195 (79.27)0.33 (0.22 to 0.52)0.43 (0.25 to 0.75)0.002
AIIRD diagnosis
PsA, n=165160 (96.97)ReferenceReference
RA, n=263216 (82.13)0.14 (0.06 to 0.37)0.31 (0.11 to 0.82)0.02
AxSpA, n=6867 (98.53)2.09 (0.24 to 18.26)2.01 (0.23 to 17.72)0.52
SLE, n=10193 (92.08)0.36 (0.12 to 1.14)0.35 (0.11 to 1.16)0.08
IIM, n=197 (36.84)0.02 (0.01 to 0.07)0.06 (0.02 to 0.27)<0.001
LVV, n=2120 (95.24)0.63 (0.07 to 5.63)0.82 (0.09 to 7.54)0.86
AAV, n=268 (30.77)0.01 (0.004 to 0.05)0.04 (0.01 to 0.17)<0.001
Other vasculitis, n=2319 (82.61)0.15 (0.04 to 0.6)0.26 (0.06 to 1.22)0.09
AIIRD treatments
Anti-CD20, n=8736 (41.38)0.05 (0.03 to 0.08)0.13 (0.07 to 0.24)<0.001
Anti-CD20 monotherapy, n=2811 (39.29)0.07 (0.03 to 0.16)0.92 (0.33 to 2.57)0.87
Anti-CD20 +MTX, n=145 (35.71)0.07 (0.02 to 0.21)0.94 (0.23 to 3.89)0.93
MTX, n=176148 (84.09)0.64 (0.4 to 1.03)0.58 (0.31 to 1.07)0.08
MTX monotherapy, n=4138 (92.68)1.75 (0.53 to 5.79)1.84 (0.5 to 6.74)0.36
GC, n=13086 (66.15%)0.16 (0.1 to 0.29)0.48 (0.26 to 0.87)0.02
TNFi, n=172167 (97.09)5.6 (2.24 to 14.0)1.89 (0.68 to 5.24)0.22
TNFi monotherapy, n=121119 (98.35)9.46 (2.3 to 38.87)2.58 (0.56 to 11.94)0.22
TNFi +MTX, n=2927 (93.1)1.86 (0.44 to 7.94)1.46 (0.31 to 6.91)0.63
IL6i, n=3737 (100)NANANA
IL6i monotherapy, n=1919 (100)NANANA
IL6i+MTX, n=77 (100)NANANA
IL17i, n=4847 (97.92)6.73 (0.92 to 49.32)1.42 (0.16 to 12.83)0.75
IL17 monotherapy, n=3737 (100)NANANA
IL17 +MTX, n=76 (85.71)0.81 (0.1 to 6.8)0.25 (0.02 to 2.7)0.25
Abatacept, n=1610 (62.5)0.21 (0.08 to 0.6)0.14 (0.04 to 0.43)<0.001
Abatacept monotherapy, n=75 (71.43)0.33 (0.06 to 1.74)0.2 (0.033 to 1.16)0.073
Abatacept+MTX, n=52 (40)0.09 (0.01 to 0.53)0.07 (0.01 to 0.48)0.007
JAKi monotherapy, n=2119 (90.48)1.29 (0.3 to 5.63)0.72 (0.15 to 3.48)0.68
JAKi+MTX, n=2422 (91.67)1.5 (0.35 to 6.48)1.78 (0.38 to 8.35)0.46
MMF, n=2818 (64.29)0.22 (0.1 to 0.5)0.1 (0.03 to 0.34)0.0013
MMF monotherapy, n=53 (60)0.2 (0.03 to 1.21)0.11 (0.02 to 0.83)0.03
  • AAV, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; AIIRD, autoimmune inflammatory rheumatic diseases; anti-CD20, CD20 inhibitors; AxSpA, axial spondyloarthritis; GC, glucocorticoids; IIM, idiopathic inflammatory myositis; IL6i, interleukin 6 inhibitors; IL17i, interleukin 17 inhibitors; JAKi, Janus kinase inhibitors; LVV, large vessel vasculitis; MMF, mycophenolate mofetil; MTX, methotrexate; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TNFi, tumour necrosis factor inhibitors.